Is Acumen Pharmaceuticals Stock a Good Investment?
Acumen Pharmaceuticals Investment Advice | ABOS |
- Examine Acumen Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Acumen Pharmaceuticals' leadership team and their track record. Good management can help Acumen Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Acumen Pharmaceuticals' business and its evolving consumer preferences.
- Compare Acumen Pharmaceuticals' performance and market position to its competitors. Analyze how Acumen Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Acumen Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Acumen Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Acumen Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Acumen Pharmaceuticals is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Acumen Pharmaceuticals Stock
Researching Acumen Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 78.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. Acumen Pharmaceuticals recorded a loss per share of 1.38. The entity had not issued any dividends in recent years.
To determine if Acumen Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Acumen Pharmaceuticals' research are outlined below:
| Acumen Pharmaceuticals generated a negative expected return over the last 90 days | |
| Acumen Pharmaceuticals has high historical volatility and very poor performance | |
| Acumen Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (52.37 M) with loss before overhead, payroll, taxes, and interest of (32.36 M). | |
| Acumen Pharmaceuticals currently holds about 189.91 M in cash with (43.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Acumen Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference |
Acumen Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Acumen Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Acumen Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Acumen Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Acumen Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-13 | 2023-09-30 | -0.27 | -0.24 | 0.03 | 11 | ||
2022-11-14 | 2022-09-30 | -0.23 | -0.26 | -0.03 | 13 | ||
2024-08-13 | 2024-06-30 | -0.28 | -0.34 | -0.06 | 21 | ||
2022-05-16 | 2022-03-31 | -0.17 | -0.23 | -0.06 | 35 | ||
2023-08-08 | 2023-06-30 | -0.35 | -0.28 | 0.07 | 20 | ||
2023-05-09 | 2023-03-31 | -0.35 | -0.28 | 0.07 | 20 | ||
2023-03-27 | 2022-12-31 | -0.25 | -0.32 | -0.07 | 28 | ||
2021-11-15 | 2021-09-30 | -0.17 | -0.1 | 0.07 | 41 |
Know Acumen Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Acumen Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acumen Pharmaceuticals backward and forwards among themselves. Acumen Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Acumen Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Laurion Capital Management Lp | 2024-09-30 | 867 K | Geode Capital Management, Llc | 2024-09-30 | 864.5 K | Hudson Bay Capital Management Lp | 2024-09-30 | 636 K | Pathstone Holdings Llc | 2024-06-30 | 480.2 K | State Street Corp | 2024-06-30 | 436.6 K | Jane Street Group Llc | 2024-06-30 | 427.7 K | Two Sigma Advisers, Llc | 2024-06-30 | 392.1 K | Two Sigma Investments Llc | 2024-09-30 | 309.5 K | Northern Trust Corp | 2024-09-30 | 308.9 K | Ra Capital Management, Llc | 2024-09-30 | 14.9 M | Franklin Resources Inc | 2024-09-30 | 3.5 M |
Acumen Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 135.78 M.Market Cap |
|
Acumen Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.20) | (0.19) |
Determining Acumen Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Acumen Pharmaceuticals is a good buy. For example, gross profit margin measures Acumen Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Acumen Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Acumen Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Acumen Pharmaceuticals. Check Acumen Pharmaceuticals' Beneish M Score to see the likelihood of Acumen Pharmaceuticals' management manipulating its earnings.
Evaluate Acumen Pharmaceuticals' management efficiency
Acumen Pharmaceuticals has return on total asset (ROA) of (0.2099) % which means that it has lost $0.2099 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3283) %, meaning that it created substantial loss on money invested by shareholders. Acumen Pharmaceuticals' management efficiency ratios could be used to measure how well Acumen Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2024. Return On Capital Employed is likely to drop to -0.22 in 2024. At this time, Acumen Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 66.7 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.51 | 5.78 | |
| Tangible Book Value Per Share | 5.51 | 5.78 | |
| Enterprise Value Over EBITDA | (2.86) | (2.72) | |
| Price Book Value Ratio | 0.70 | 0.73 | |
| Enterprise Value Multiple | (2.86) | (2.72) | |
| Price Fair Value | 0.70 | 0.73 | |
| Enterprise Value | 102.6 M | 97.5 M |
The management team at Acumen Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 0.039 |
Basic technical analysis of Acumen Stock
As of the 28th of November, Acumen Pharmaceuticals shows the Mean Deviation of 3.56, risk adjusted performance of (0.04), and Standard Deviation of 4.75. Acumen Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Acumen Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Acumen Pharmaceuticals is priced correctly, providing market reflects its regular price of 2.2 per share. Please also double-check Acumen Pharmaceuticals jensen alpha, which is currently at (0.36) to validate the company can sustain itself at a future point.Acumen Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acumen Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acumen Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acumen Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schacterle Amy over three weeks ago Insider Trading | ||
Barton Russell over two months ago Acquisition by Barton Russell of 135000 shares of Acumen Pharmaceuticals at 5.19 subject to Rule 16b-3 | ||
Ives Jeffrey L. over three months ago Disposition of 2800 shares by Ives Jeffrey L. of Acumen Pharmaceuticals at 1.19 subject to Rule 16b-3 | ||
Stalfort John A Iii over six months ago Disposition of 131595 shares by Stalfort John A Iii of Acumen Pharmaceuticals subject to Rule 16b-3 | ||
Meisner Derek M over six months ago Sale by Meisner Derek M of 8933 shares of Acumen Pharmaceuticals | ||
Ives Jeffrey L over a year ago Exercise or conversion by Ives Jeffrey L of 149 shares of Acumen Pharmaceuticals subject to Rule 16b-3 | ||
Ra Capital Management Lp over a year ago Purchase by Ra Capital Management Lp of 5161290 shares of Acumen Pharmaceuticals | ||
Ives Jeffrey L over a year ago Acquisition by Ives Jeffrey L of 25000 shares of Acumen Pharmaceuticals subject to Rule 16b-3 |
Acumen Pharmaceuticals' Outstanding Corporate Bonds
Acumen Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Acumen Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Acumen bonds can be classified according to their maturity, which is the date when Acumen Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ACTIVISION BLIZZARD INC Corp BondUS00507VAQ23 | View | |
| US00507VAP40 Corp BondUS00507VAP40 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAM19 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAK52 | View | |
| ACTAVIS FDG SCS Corp BondUS00507UAS06 | View |
Understand Acumen Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Acumen Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (1.52) | |||
| Mean Deviation | 3.56 | |||
| Coefficient Of Variation | (1,459) | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.54 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.36) | |||
| Total Risk Alpha | (1.05) | |||
| Treynor Ratio | (1.53) | |||
| Maximum Drawdown | 28.07 | |||
| Value At Risk | (6.78) | |||
| Potential Upside | 7.52 | |||
| Skewness | (0.32) | |||
| Kurtosis | 1.57 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (1.52) | |||
| Mean Deviation | 3.56 | |||
| Coefficient Of Variation | (1,459) | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.54 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.36) | |||
| Total Risk Alpha | (1.05) | |||
| Treynor Ratio | (1.53) | |||
| Maximum Drawdown | 28.07 | |||
| Value At Risk | (6.78) | |||
| Potential Upside | 7.52 | |||
| Skewness | (0.32) | |||
| Kurtosis | 1.57 |
Consider Acumen Pharmaceuticals' intraday indicators
Acumen Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Acumen Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Acumen Pharmaceuticals Corporate Filings
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 6th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 13th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 10th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Acumen Stock media impact
Far too much social signal, news, headlines, and media speculation about Acumen Pharmaceuticals that are available to investors today. That information is available publicly through Acumen media outlets and privately through word of mouth or via Acumen internal channels. However, regardless of the origin, that massive amount of Acumen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Acumen Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Acumen Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Acumen Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Acumen Pharmaceuticals alpha.
Acumen Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Acumen Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Acumen Pharmaceuticals Corporate Management
| Julie Bockenstette | Ex HR | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Siew MS | Assistant Operations | Profile | |
| Robyn MA | Associate Communications | Profile |
Already Invested in Acumen Pharmaceuticals?
The danger of trading Acumen Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acumen Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acumen Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acumen Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.